Amer Bio Medica

PINK:ABMC USA Diagnostics & Research
Market Cap
$4.81K
Market Cap Rank
#46506 Global
#14485 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
$0.00 - $0.00
All Time High
$1.19
About

American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rap… Read more

Amer Bio Medica - Asset Resilience Ratio

Latest as of June 2001: 0.76%

Amer Bio Medica (ABMC) has an Asset Resilience Ratio of 0.76% as of June 2001. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$28.00K
Cash + Short-term Investments
Total Assets
$3.69 Million
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (1996–2001)

This chart shows how Amer Bio Medica's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Amer Bio Medica's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $28.00K 0.76%
Total Liquid Assets $28.00K 0.76%

Asset Resilience Insights

  • Limited Liquidity: Amer Bio Medica maintains only 0.76% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Amer Bio Medica Industry Peers by Asset Resilience Ratio

Compare Amer Bio Medica's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ADCNF
OTCGREY:ADCNF
Diagnostics & Research 1.12%
Berry Genomics Co Ltd
SHE:000710
Diagnostics & Research 0.45%
NSN Co. Ltd
KQ:031860
Diagnostics & Research 1.72%
JOONGANG DNM Co.Ltd
KQ:051980
Diagnostics & Research 27.26%
GeneMatrix Inc
KQ:109820
Diagnostics & Research 41.52%
Genoray Co. Ltd
KQ:122310
Diagnostics & Research 0.03%
Green Cross Lab Cell Corporation
KQ:144510
Diagnostics & Research 0.18%
Optipharm.CO.LTD
KQ:153710
Diagnostics & Research 20.73%

Annual Asset Resilience Ratio for Amer Bio Medica (1996–2001)

The table below shows the annual Asset Resilience Ratio data for Amer Bio Medica.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2001-12-31 1.45% $74.00K $5.09 Million -0.01pp
2000-12-31 1.47% $74.00K $5.04 Million -14.74pp
1999-12-31 16.21% $719.00K $4.43 Million +2.90pp
1998-12-31 13.31% $719.00K $5.40 Million -12.33pp
1997-12-31 25.64% $1.05 Million $4.11 Million 0.00pp
1996-12-31 25.64% $1.05 Million $4.11 Million --
pp = percentage points